GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (OTCPK:BIOAF) » Definitions » Other Operating Expense

Bioasis Technologies (Bioasis Technologies) Other Operating Expense : $0.00 Mil (TTM As of Nov. 2022)


View and export this data going back to 2009. Start your Free Trial

What is Bioasis Technologies Other Operating Expense?

Bioasis Technologies's Other Operating Expense for the three months ended in Nov. 2022 was $-0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Nov. 2022 was $0.00 Mil.

Bioasis Technologies's quarterly Other Operating Expense increased from May. 2022 ($0.00 Mil) to Aug. 2022 ($0.00 Mil) but then declined from Aug. 2022 ($0.00 Mil) to Nov. 2022 ($-0.00 Mil).

Bioasis Technologies's annual Other Operating Expense declined from Feb. 2020 ($0.00 Mil) to Feb. 2021 ($0.00 Mil) but then increased from Feb. 2021 ($0.00 Mil) to Feb. 2022 ($0.00 Mil).


Bioasis Technologies Other Operating Expense Historical Data

The historical data trend for Bioasis Technologies's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Other Operating Expense Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bioasis Technologies Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioasis Technologies Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioasis Technologies (Bioasis Technologies) Business Description

Traded in Other Exchanges
N/A
Address
157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.